'Disruption' In Action: Lilly Tries To Upend PD1 Pricing – But Instead Upsets US FDA
Executive Summary
Lilly set out to “disrupt” US pricing models for checkpoint inhibitors by working with Innovent to seek US FDA approval of sintilimab. Did it end up disrupting its own relationship with the FDA?